Clinical Trials

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07124936 2025-08-15

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Phase 1/2 Recruiting

97 enrolled

LymphoidOther solid neoplasm

Lymphoma, Large B-Cell, Diffuse

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Recruiting

480 enrolled

Advanced Solid Tumor

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT06601504 2025-06-06

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 2 Active not recruiting

61 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

272 enrolled

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT06854445 2025-03-24

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

55 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

416 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Lymphoma, Large B-Cell, Diffuse

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03435250 2024-07-25

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

123 enrolled

Phase 3 Active not recruiting

Lymphoma

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

93 enrolled 19 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, T-Cell

NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Phase 1/2 Completed

13 enrolled 17 charts

LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Phase 2 Completed

71 enrolled 15 charts

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04313608 2024-03-25

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

23 enrolled 17 charts

Lymphoma, B-Cell

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Unknown

75 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

DermatologicHead & NeckLymphoidThoracic

159 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03488251 2022-08-16

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

8 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT01321541 2021-11-19

PIX-R

Phase 3 Completed

312 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoma, B-Cell

NCT02951156 2020-12-17

Javelin DLBCL

Phase 3 Terminated

29 enrolled 24 charts

Lymphoma, Large B-Cell, Diffuse

NCT00436280 2020-08-06

Chemotherapy for Participants With Lymphoma

Phase 2 Completed

68 enrolled 20 charts

Lymphoma, Large B-Cell, Diffuse

NCT04500561 2020-08-05

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Phase 1/2 Unknown

28 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

19 enrolled

GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

NCT01564251 2020-02-25

A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma

104 enrolled

Lymphoma

NCT00088530 2020-02-05

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Phase 3 Completed

140 enrolled 15 charts

Lymphoma, Non-Hodgkin

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Phase 3 Terminated

338 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

BreastGastrointestinalLymphoid

5 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

172 enrolled 13 charts

Lymphoma, Neoplasms

NCT00475917 2015-08-21

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

28 enrolled

Lymphoma, Neoplasms

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

44 enrolled